ESSA Pharma Inc. Files 8-K
| Field | Detail |
|---|---|
| Company | Essa Pharma Inc. |
| Form Type | 8-K |
| Filed Date | Jul 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, financial-reporting
TL;DR
ESSA Pharma filed an 8-K on 7/23/25. Standard corporate update.
AI Summary
ESSA Pharma Inc. filed an 8-K on July 23, 2025, reporting other events and financial statements. The filing details the company's incorporation in British Columbia, Canada, and provides its principal executive office address in Vancouver.
Why It Matters
This filing serves as a public record of ESSA Pharma Inc.'s corporate activities and financial reporting, providing transparency for investors and stakeholders.
Risk Assessment
Risk Level: low — This is a routine corporate filing (8-K) with no immediate material financial events or disclosures that would suggest a high risk.
Key Numbers
- 001-37410 — SEC File Number (Identifies the company's filing with the SEC.)
- 98-1250703 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ESSA Pharma Inc. (company) — Registrant
- July 23, 2025 (date) — Date of earliest event reported
- Vancouver, British Columbia, Canada (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for ESSA Pharma Inc.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 23, 2025.
Where is ESSA Pharma Inc. incorporated?
ESSA Pharma Inc. is incorporated in British Columbia, Canada.
What is the address of ESSA Pharma Inc.'s principal executive offices?
The principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5.
What is the company's telephone number?
The company's telephone number is (778) 331-0962.
What is the SIC code for ESSA Pharma Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 23, 2025 regarding ESSA Pharma Inc..